FDA partially halts leukemia studies of Gilead cancer drug August 21, 2023 San Francisco Biotechnology Network News News, Syndication Comments Off on FDA partially halts leukemia studies of Gilead cancer drug The hold is the latest setback for a drug that was the center of Gilead’s $5 billion acquisition of biotech Forty Seven in 2020. Click here to view original post